Madrigal Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Sibold
- Full Time Employees
- 528
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Four Tower Bridge West Conshohocken PA United States of America 19428
- IPO Date
- Feb 6, 2007
- CIK
- 0001157601
- Website
- madrigalpharma.com
- Similar Companies
- Business
- Madrigal Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative therapies for severe liver conditions. The company's primary focus lies in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), a disease with considerable unmet medical needs. Its leading therapeutic, Rezdiffra (resmetirom), an oral, liver-directed selective thyroid hormone receptor-β agonist, received accelerated approval from the U.S. Food and Drug Administration in March 2024 for adults with noncirrhotic MASH featuring moderate to advanced liver fibrosis. Rezdiffra has also secured approval from the European Commission for this indication. Madrigal continues to advance its clinical program, evaluating Rezdiffra in an ongoing Phase 3 outcomes trial for patients with compensated MASH cirrhosis. Additionally, the company is progressing an oral GLP-1 development candidate, MGL-2086, slated to enter clinical trials in early 2026, with potential for combination therapy alongside Rezdiffra. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals Could Become The Next Vertex
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)